Neoplasms Clinical Trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 188 clinical trials
A Phase I/II trial of olaparib palbociclib and fulvestrant in patients with BRCA mutation-associated hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer

The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+) breast cancer and BRCA1 or BRCA2 mutations.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 2/3 Randomized Open-Label Study of Toca 511 a Retroviral Replicating Vector Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

This is a multicenter, randomized, open-label study of Toca 511 and Toca FC versus standard of care (SOC) that comprises Investigators choice of either single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of glioblastoma or anaplastic astrocytoma. …

  • 0 views
  • 19 Feb, 2024
  • 1 location
IMAGING OF PRIMARY OR RECURRENT GYNECOLOGICAL CANCER WITH [18F]FLUORTHANATRACE ([18F]FTT) PET/CT

Women with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 30 evaluable subjects who have been recommended to start systemic therapy as part of …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Clinical trial of TC-210 T CELLS in Patients with Advanced Mesothelin Expressing Cancer

Your partner is participating in a research study which is looking to determine the safety and efficacy of the drug product, TC-210 T Cells. Your partner has received theTC-210 T Cells. You are being asked to provide information to the Sponsor and your partner’s study doctor, because your partner has …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Identification of neoantigen-specific T cell responses in cancer patients within the Penn Medicine BioBank

You are being asked to participate in this research investigation because you have expressed an interest in participating in a study to better understand how the immune cells of the body recognize and fight cancer.

  • 0 views
  • 19 Feb, 2024
  • 1 location
The Association Between CBT-I Dose and Innate Immunity in Insomnia and Fatigue in Prostate Cancer Patients

  Cognitive Behavioral Therapy for Insomnia (CBT-I) has been shown to be an effective treatment for insomnia in both cancer and non-cancer populations. However, CBT-I has yet to demonstrate an effect on cancer-related fatigue. This study aims to see whether an increased amount of CBT-I sessions decreases the amount of …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 1/2 Study of Oral LOXO-292 in Patients

LOXO-292 is a highly potent and specific inhibitor of the RET RTK, with minimal inhibition of other kinase and non-kinase targets, and therefore may be of benefit to patients with tumors (such as NSCLC, MTC, PTC, and colon or breast carcinomas) that harbor RET alterations and/or depend on RET activation. …

  • 0 views
  • 19 Feb, 2024
  • 1 location
BRCA Founder OutReach (BFOR) Study

 BFOR seeks to increase access to testing for one of the most common tests for hereditary cancer, BRCA genetic mutations. These mutations of BRCA genes are associated with greater risks for several types of cancer, including breast, ovarian, and prostate cancer.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 3 Randomized Single Dose Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

To confirm the efficacy of OTL38 in combination with fluorescent light to detect additional Folate Receptor-positive (FR+) ovarian cancer lesions

  • 0 views
  • 19 Feb, 2024
  • 1 location
IMAGING OF IN VIVO SIGMA-2 RECEPTOR EXPRESSION WITH [18F]ISO-1 POSITRON EMISSION TOMOGRAPHY (PET/CT) IN METASTATIC BREAST CANCER

   Results of the standard breast cancer pathology immunohistochemistry (IHC) panel (usually estrogen receptor (ER), progesterone receptor (PgR) and HER2/neu) will be collected from the medical record for both metastatic breast cancer biopsy and primary breast cancer biopsy or surgery, when available.

  • 0 views
  • 19 Feb, 2024
  • 1 location